Sequenom Eyes $100M in Private Notes Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Monday it plans to offer $100 million in convertible senior notes due 2017.

Proceeds from the private offering will be used to continue commercialization of its MaterniT21 Plus LDT non-invasive aneuploidy test and for general corporate purposes, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.